Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives

Cancer/Radiotherapie

Volumn 18, Issue 5-6, 2014, Pages 391-395

  Rekers, N H ^a   Troost, E G C ^a   Zegers, C M L ^a   Germeraad, W T V ^a   Dubois, L J ^a   Lambin, P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Immunotherapy; Stereotactic ablative body radiotherapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; IPILIMUMAB; LIPOCORTIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; CD137 ANTIGEN; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

BREAST CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE COURSE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIMARY TUMOR; RADIATION DOSE; RADIOTHERAPY; SHORT SURVEY; SOLID TUMOR; STEREOTACTIC ABLATIVE BODY RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BYSTANDER EFFECT; CELL DEATH; DRUG EFFECTS; FORECASTING; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; BYSTANDER EFFECT; CELL DEATH; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DOSE FRACTIONATION; FORECASTING; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 84907389151     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2014.06.012     Document Type: Short Survey

References (54)

1. Jaffray D.A. Image-guided radiotherapy: from current concept to future perspectives. Nature reviews. Clin Oncol 2012, 9:688-699.
2. van Baardwijk A., Tomé W.A., van Elmpt W., Bentzen S.M., Reymen B., Wanders R., et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012, 105:145-149.
3. Ashworth A., Rodrigues G., Boldt G., Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013, 82:197-203.
4. Cheruvu P., Metcalfe S.K., Metcalfe J., Chen Y., Okunieff P., Milano M.T. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol 2011, 6:80.
5. Dahele M., Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011, 43:75-82.
6. Hasselle M.D., Haraf D.J., Rusthoven K.E., Golden D.W., Salgia R., Villaflor V.M., et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:376-381.
7. Higginson D.S., Chen R.C., Tracton G., Morris D.E., Halle J., Rosenman J.G., et al. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2012, 84:e385-e392.
8. Marks L.B., Saynak M., Christodouleas J.P. Stage III vs. stage IV lung cancer: “Crossing a Great Divide“. Lung Cancer 2010, 67:1-3.
9. Milano M.T., Katz A.W., Zhang H., Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012, 83:878-886.
10. Tree A.C., Khoo V.S., Eeles R.A., Ahmed M., Dearnaley D.P., Hawkins M.A., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14:e28-e37.
11. De Ruysscher D., Wanders R., van Baardwijk A., Dingemans A.M., Reymen B., Houben R., et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (NCT01282450). J Thorac Oncol 2012, 7:1547-1555.
12. Keast D. Immunosurveillance and cancer. Lancet 1970, 2:710-712.
13. Demaria S., Bhardwaj N., McBride W.H., Formenti S.C. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005, 63:655-666.
14. Formenti S.C., Demaria S. Radiation therapy to convert the tumour into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012, 84:879-880.
15. McBride W.H., Chiang C.S., Olson J.L., Wang C.C., Hong J.H., Pajonk F., et al. A sense of danger from radiation. Radiat Res 2004, 162:1-19.
16. Chakraborty M., Abrams S.I., Camphausen K., Liu K., Scott T., Coleman C.N., et al. Irradiation of tumour cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
17. Garnett, Palena C., Chakraborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumour cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
18. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59.
19. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
20. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J Exp Med 2006, 203:1259-1271.
21. Kroemer G., Zitvogel L. Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012, 1:407-408.
22. Masucci G.V., Wersäll P., Kiessling R., Lundqvist A., Lewensohn R. Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. J Transl Med 2012, 10:104.
23. Mole R.H. Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26:234-241.
24. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
25. Stamell E.F., Wolchok J.D., Gnjatic S., Lee N.Y., Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85:293-295. [Epub 2012 May 5]. 10.1016/j.ijrobp.2012.03.017.
26. Kachikwu E.L., Iwamoto K.S., Liao Y.P., DeMarco J.J., Agazaryan N., Economou J.S., et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 2011, 81:1128-1135.
27. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997, 94:8099-8103.
28. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
29. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
30. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
31. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
32. Flemming A. Immunotherapy: a vaccine for prostate cancer?. Nat Rev Cancer 2011, 11:539.
33. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., et al. Phase III trial of bevacizumab plus interferon Alfa versus interferon Alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
34. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18:1751-1759.
35. Moudgil T., Bell R.B., Leidner R., Van de Ven R., Feng Z., Affentoulis M., et al. Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck. J Immuno Ther 2013, 1:P262.
36. Nizard M., Sandoval F., Badoual C., Pere H., Terme M., Hans S., et al. Immunotherapy of HPV-associated head and neck cancer: critical parameters. Oncoimmunology 2013, 2:e24534.
37. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., et al. Therapeutic effects of ablative radiation on local tumour require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
38. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumours increases the generation of tumour antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
39. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
40. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
41. Verbrugge I., Hagekyriakou J., Sharp L.L., Galli M., West A., McLaughlin N.M., et al. Radiotherapy increases the permissiveness of established mammary tumours to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163-3174.
42. Deng L., Liang H., Burnette B., Beckett M., Darga T., Weichselbaum R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumour immunity in mice. J Clin Invest 2014, 124:687-695.
43. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., et al. Ionizing radiation inhibition of distant untreated tumours (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
44. Shiraishi K., Ishiwata Y., Nakagawa K., Yokochi S., Taruki C., Akuta T., et al. Enhancement of antitumour radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res 2008, 14:1159-1166.
45. Everse L.A., Bernsen M.R., Dullens H.F., Den Otter W. Priming of the antitumour response promotes efficacy of interleukin-2 therapy. Cancer Immunol Immunother 1997, 44:221-229.
46. Jurgenliemk-Schulz I.M., Renes I.B., Rutgers D.H., Everse L.A., Bernsen M.R., Den Otter W., et al. Anti-tumour effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Invest 1997, 5:54-61.
47. Frey B., Schildkopf P., Rödel F., Weiss E.M., Munoz L.E., Herrmann M., et al. Annexin A5 renders dead tumour cells immunogenic: implications for multimodal cancer therapies. J Immunotoxicol 2009, 6:209-216.
48. Witek M., Blomain E.S., Magee M.S., Xiang B., Waldman S.A., Snook A.E. Tumour radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 2014, 88:1188-1195.
49. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
50. Hiniker S.M., Chen D.S., Knox S.J. Abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:2035. [author reply 2035-6].
51. Stamell E.F., Wolchok J.D., Gnjatic S., Lee N.Y., Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2013, 85:293-295.
52. Slovin S.F., Higano C.S., Hamid O., Tejwani S., Harzstark A., Alumkal J.J., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013, 24:1813-1821.
53. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A., van den Eertwegh A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712. [Epub 2014 May 13]. 10.1016/S1470-2045(14)70189-5.
54. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world 2014, US National Institutes of Health©, Bethesda, MD, www.clinicaltrials.gov [home page on Internet].